<DOC>
	<DOCNO>NCT01585259</DOCNO>
	<brief_summary>Investigate safety efficacy Anfibatide non-ST segment myocardial infarction patient</brief_summary>
	<brief_title>Anfibatide Phase Ib-IIa Clinical Trial</brief_title>
	<detailed_description>1 . This study phase Ib-IIa exploratory study observe safety Antiplatelet Thrombolysin Injection treatment non-ST segment myocardial infarction ( NSTEMI ) patient preliminarily evaluate efficacy different dos , provide theoretical basis phase II III clinical study protocol . 2 . To investigate pharmacokinetics different dos .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>1 . Aged 1870 year ; 2 . Laboratory test show increase marker myocardial damage ( CKMB , CTnI ) , reduction increase , least one value exceed 99th percentile upper limit reference value ; 3 . Ischemia symptom ( ischemic chest pain last 15 minute , little release take nitroglycerin sublingually ) new myocardial ischemia electrocardiogram ( ECG ) , i.e . new STT variation ( new transient depression ST segment 0.1mV , Twave inversion≥0.2mV ) ; 4 . Patients receive PCI coronary angiography ; 5 . Patients , family guardian give sign informed consent form . 1 . Patients severe unstable hemodynamics receive urgent PCI ; 2 . Patients untreated hypertension ( SBP &gt; 180 mmHg DBP &gt; 110mmHg ) hypotension shock ( SBP &lt; 90mmHg/80mmHg 30min ) ; 3 . Investigator considers patient need use GPIIb/IIIa receptor antagonist study period ; 4 . After coronary angiography , number stenosed vessel ＞2；lesions leave main branch , severe calcification artery graft lesion ; 5 . Patients heart function decompensatory phase ( Killip grade 34 ) cardiac shock ; 6 . Patients malignant arrhythmia , e.g . thirddegree atrioventricular block , ventricular tachycardia fibrillation ventricular ; 7 . Patients severe hepatic renal dysfunction , serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) exceed 1.5 time upper limit reference value , creatinine clearance ＜30ml/min serum creatinine ≥200μmol/L 2.5mg/dl ; 8 . Patients receive PCI past six month ; 9 . Patients receive coronary artery bypass grafting ( CABG ) previously ; 10 . Patients receive invasive operation past 3 month ; 11 . Patients suffer ischemic stroke transient ischemic attack ( TIA ) past 6 month , patient past history hemorrhagic stroke ; 12 . Patients need longterm treatment oral anticoagulant ( warfarin ) ; 13 . Patients active peptic ulcer , diseases hemorrhagic tendency ; 14 . Patients disease coagulation disorder ; 15 . Hematology test show platelet count ＜100,000mm3 , hemoglobin＜100g/L ; 16 . Women pregnant lactation period , woman childbearing age take efficient contraception measure ; 17 . Patients allergic constitution ; 18 . Patients participate clinical trial ; 19 . Patients give sign informed consent form ; 20 . Patients suitable enroll trial accord investigator 's judgement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>anti-platelet ;</keyword>
	<keyword>safety ;</keyword>
	<keyword>efficacy</keyword>
</DOC>